Currentsierra health and lifePolicy 2026T0362RR

Bariatric Surgery

This section summarizes clinical evidence, comparative outcomes, long-term results, and revisional surgery data for multiple bariatric procedures (BPD/DS, RYGB, sleeve gastrectomy, LAGB, robotic-assisted approaches) and revisional procedures; it is part 2 of a multi-part policy document and contains literature review conclusions rather than explicit coverage rules.

Policy Summary

Payersierra health and life

PolicyBariatric Surgery

Policy CodePolicy N/A

Change TypeRevisions and additions to coverage criteria, documentation, and unproven procedures

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionSubmit required medical records documenting procedure type/status, preoperative evaluation, physical activity, recent diagnostic test results, treatment plan, and structured diet program completion per COMAR when applicable.

SourceLink

POLICY UPDATE CHANGES

Replaced references to 'Nonalcoholic Fatty Live Disease (NAFLD)' with 'Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)'.

Revised coverage criteria for a planned two-stage procedure and changed wording from 'compliant with' to 'adherent to' nutrition and exercise.

Added unproven/not medically necessary procedures: Silastic ring vertical gastric bypass; Transoral endoscopic surgery including transoral outlet reduction (TORe).

Removed 'stomach aspiration therapy' from the unproven/not medically necessary list.

Replaced and consolidated various transoral endoscopic and device categories to group them under 'transoral endoscopic surgery including ...' (gastrointestinal liners, intragastric balloon, endoscopic sleeve gastroplasty including OverStich™).

Updated required medical records documentation for reviews, including adding items and replacing some historical requirements (e.g., two-year BMI history replaces five-year).

Added Maryland fully insured group policy guidance to follow COMAR 31.10.33.03B/03.04 including BMI thresholds, age, psychological exam, and structured diet program documentation requirements.

Updated Supporting Information sections: Description of Services, Clinical Evidence, FDA, and References to reflect current information.

Coverage Summary & Scope

This document is Part 2 of 7 of the Bariatric Surgery policy and summarizes the clinical evidence, comparative outcomes, long‑term results, and revisional surgery data rather than setting explicit coverage rules. The policy status is CURRENT and the subject is Bariatric Surgery — clinical evidence and outcomes (part 2 of 7). The policy number is 2026T0362RR and the policy effective date is May 1, 2026.

Key thresholds (BMI, device indications, limb-length nutrition risk)

Adult BMI — standard coverage thresholdMBS recommended / proven when BMI ≥ 40 kg/m2 (or ≥ 37.5 kg/m2 for Asian descent); coverage considered for BMI 35–39.9 kg/m2 with ≥1 obesity-related comorbidity; consider MBS for BMI 30–34.9 kg/m2 with metabolic disease

Adult BMI — ADA/AACE/ASMBS adjustment for Asian ancestryLower thresholds by 2.5 kg/m2 for Asian patients (e.g., consider surgery at BMI ≥ 27.5 or offer at BMI ≥ 25 per guidance)

Maryland (COMAR) fully insured group policy BMI thresholdsBMI > 40 kg/m2 without comorbidity OR BMI ≥ 35 kg/m2 with obesity-related medical conditions (eg, hypertension, cardiopulmonary condition, sleep apnea, diabetes, weight-induced life‑threatening condition); age ≥ 18

Pediatric / Adolescent BMI selection (ASMBS/AAP)Adolescent: BMI ≥ 20% of 95th percentile with a comorbidity OR ≥ 140% of 95th percentile (Class III); AAP: Class II = BMI ≥ 35 or 120% of 95th percentile with clinically significant disease; Class III = BMI ≥ 40 or 140% of 95th percentile

Orbera (IGB) FDA indication BMI rangeBMI ≥ 30 kg/m2 and ≤ 40 kg/m2; temporary device with maximum placement period ~6 months

TransPyloric Shuttle FDA indication BMI rangesBMI 35.0–40.0 kg/m2 OR BMI 30.0–34.9 kg/m2 with ≥1 obesity-related comorbid condition; intended for up to 12 months use

DJBL / EndoBarrier safety thresholds (risk signals)Pooled early removal ≈ 19% and pooled SAE incidence ≈ 17% (including hepatic abscess) — informs device risk considerations

Revisional RYGB distalization nutrition-risk limb-length thresholdsCommon channel (CC) < 200 cm and total alimentary limb length (TALL = AL + CC) < 400 cm associated with increased risk of severe macro- and micronutrient deficiencies; require aggressive supplementation and monitoring

Maryland (COMAR) Coverage Criteria and Documentation Requirements

Coverage when ALL of the following COMAR-specified criteria are met

Covered when ALL of the following COMAR-specified criteria are met:

ALL of the following

ONE of the following obesity thresholds
- Body Mass Index (BMI) of ≥ 40 kg/m2 (or BMI ≥ 37.5 kg/m2 in individuals of Asian descent)
- - Obesity-related co-morbid conditions
    Insulin resistance or type 2 diabetes
    Cardiovascular disease (e.g., history of stroke and/or myocardial infarction, poorly controlled hypertension despite pharmacotherapy, coronary artery disease, hyperlipidemia)

Clinical Evidence Summaries by Procedure / Device

Evidence summaries and conclusions by device/therapy

Statements on efficacy/safety and evidence gaps for specific devices and therapies:

Dual IGB/DUO trial: Dual intragastric balloon system (DBS) - RCT (DUO vs DIET): participants BMI 30-40 kg/m2; co-primary endpoints met at 24 weeks; DUO had greater %EWL (ITT 25.1% vs DIET 11.3%) and higher responder rate; accommodative symptoms generally abated; balloon deflation 6%, early retrieval 9%, gastric ulcers observed (10% reduced after device change).

TransPyloric Shuttle device - evidence inconclusive per ECRI (2019); single RCT low risk of bias but not conclusive; case series high risk of bias; limited long-term follow-up.

Transoral endoscopic gastrointestinal bypass device - feasibility study (Sandler et al., 2018): n=32, 12-month mean 44.8% EWL, 17.6% total body weight loss; limited by no comparator, small N, short follow-up.

StomaphyX (endoscopic plication) - randomized single-blinded trial stopped early for futility; primary efficacy outcome achieved 22.2% with device vs 3.4% sham; one causally related AE required laparoscopic repair.

Professional Society Recommendations

Society guideline recommendations (selection, BMI thresholds, and perioperative care)

Key recommendations from professional societies regarding indications and perioperative care:

ADA (2024): consider metabolic surgery for patients with diabetes and BMI ≥ 30 kg/m2 (≥ 27.5 kg/m2 for Asian Americans); provide long-term lifestyle support and routine micronutrient monitoring after surgery.BMI >=30 (>=27.5 Asian)

AACE/Obesity Society/ASMBS: Patients with BMI ≥ 40 kg/m2 eligible; BMI ≥ 35 kg/m2 with ≥1 severe obesity-related complication should be considered; patients with BMI 30-34.9 kg/m2 with T2D and inadequate control despite optimal therapy should be considered.BMI thresholds as stated

ASMBS/IFSO (2023): MBS recommended for BMI ≥ 35 kg/m2 regardless of comorbidities; consider MBS for metabolic disease with BMI 30-34.9 kg/m2; adjust BMI thresholds for Asian populations (BMI ≥ 25 suggests clinical obesity; BMI ≥ 27.5 offer MBS).

Procedures Endorsed by ASMBS

Procedures the ASMBS endorses as acceptable bariatric options

Procedures the ASMBS endorses as acceptable bariatric options:

Sleeve gastrectomy

ASMBS endorsed procedure

Roux-en-Y gastric bypass (RYGB)

Biliopancreatic diversion with duodenal switch (BPD/DS)

SADI-S: Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S)

OAGB: One-anastomosis gastric bypass (OAGB)

Pediatric / Adolescent Bariatric Surgery Guidance

ASMBS pediatric guidance for adolescent patient selection and program requirements

ASMBS pediatric guidance for adolescent patient selection and program requirements. Preserve recommendations and BMI cutoff language as leaf nodes.

ALL of the following

Patient selection - BMI criteria
- Class III obesity (adolescent definition: 140% of the 95th percentile height-for-age or an absolute BMI ≥ 40 kg/m2, whichever is lower)
  ASMBS pediatric guidance
- Class II obesity (adolescent definition: 120% of the 95th percentile height-for-age or an absolute BMI 35–39.9 kg/m2, whichever is lower) in the presence of one or more major comorbidities (e.g., insulin resistance or type 2 diabetes; poorly controlled hypertension despite pharmacotherapy; hyperlipidemia; obstructive sleep apnea with AHI or RDI ≥ 30; metabolic dysfunction-associated steatotic liver disease; idiopathic intracranial hypertension)
  ASMBS pediatric guidance
Programmatic and evaluation requirements

Revisional Bariatric Surgery: Outcomes and Nutritional Considerations

Guidance regarding limb lengths and nutritional risk with revisional RYGB distalization

Guidance regarding limb lengths and nutritional risk with revisional RYGB distalization:

Nutritional risk thresholds: Distalization (lengthening biliopancreatic limb/shortening common channel) results in significant weight loss but increases risk of severe macro- and micronutrient deficiencies, especially if common channel < 200 cm and total alimentary limb length (AL+CC, TALL) < 400 cm.CC < 200 cm; TALL < 400 cm

Recommend aggressive vitamin supplementation and regular nutrition monitoring after distalization

Monitoring and supplementation: Patients who undergo distalization should adhere to aggressive vitamin supplementation and regular nutrition monitoring to avoid nutritional complications

Revisional bariatric surgery can produce meaningful weight and metabolic improvements but is associated with higher complication rates and uncertain comparative effectiveness. Systematic reviews and meta-analyses report clinically significant post-revision weight loss (example pooled EWL ~45%–60% at 6–24 months) but also consistently higher perioperative and overall complication rates versus primary operations (e.g., 41% vs 15% in one series). Hayes HTAs and several systematic reviews rate the body of evidence for specific revisional techniques as low to very low quality, note heterogeneity in indications and outcomes, and conclude that evidence is insufficient to establish superiority of specific revisional procedures.

Unproven and Not Medically Necessary Procedures (Revised List)

Procedures considered unproven or not medically necessary as revised

Procedures considered unproven or not medically necessary as revised:

Added - Silastic ring vertical gastric bypass: Added: Silastic ring vertical gastric bypass

Newly added to unproven/not medically necessary list

Added - Transoral endoscopic surgery incl TORe: Added: Transoral endoscopic surgery including transoral outlet reduction (TORe)

Newly added

Removed - stomach aspiration therapy: Removed: stomach aspiration therapy (no longer listed as unproven/not medically necessary)

Removed from list

Required Provider Actions and Documentation

Documentation Required

Submit required medical records for review

Submit medical records that clearly identify the procedure requested and its status (initial, planned two-stage, revision, or removal) and include the following specific items for review: procedure type/status, preoperative evaluation, physical activity patterns, results of recent relevant diagnostic testing, physician’s treatment plan, adolescent obesity class (if age 12–17), and current plus two-year BMI history.

Procedure type and whether request is initial / planned two-stage / revision / removal
Preoperative evaluation (detailed weight history, dietary and physical activity patterns)
Physical activity patterns
Results of recent relevant diagnostic testing
Physician’s treatment plan
Adolescent obesity class (for patients aged 12–17)
Current and two-year BMI history

Definitions and Abbreviations

Term	Definition
EWL
Excess Weight Loss
TWL
Total Body Weight Loss
TWL/TBWL
TBE
Transcatheter Bariatric Embolization
GES
Gastric Electrical Stimulation
LGCP
Laparoscopic Greater Curvature Plication
OAGB / MGB
One-Anastomosis Gastric Bypass / Mini-Gastric Bypass
SADI-S / SADS
Single-Anastomosis Duodeno-Ileal Switch / Single-Anastomosis Duodenal Switch
RYGB
Roux-en-Y Gastric Bypass
LSG / VSG
Laparoscopic Sleeve Gastrectomy / Vertical Sleeve Gastrectomy
ESG
Endoscopic sleeve gastroplasty (OverStitch/Apollo system)
DJBL
Duodenal-jejunal bypass liner (EndoBarrier)
IGB
Intragastric balloon
MBS
Metabolic and bariatric surgery
VBLOC
Vagus nerve blocking therapy
Revisional bariatric surgery
Any operation after the first bariatric operation that qualified toward center of excellence volume requirements; subdivided into corrective operations and conversions
TALL
Total alimentary limb length (AL plus common channel)
MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (replacement term for NAFLD)

Selected Evidence & Outcomes (Representative Studies)

Label (study)	Value (finding)
Kapeluto et al. (2020)
BPD/DS maintained ~90% diabetes remission at 10 years in study cohort
SADISLEEVE multicenter RCT (Robert et al.; SADI-S vs RYGB, 381 pts)
At 2 years mean %EWL higher with SADI-S (-76.0% vs -68.1%); MD -6.72%; SAEs similar but different profiles; 20% missing primary outcome
REDUCE/DUO trial (Ponce et al.) dual intragastric balloon (DBS)
24-week ITT %EWL 25.1% (DUO) vs 11.3% (diet); responder rate ~49% ITT; device AEs: deflation 6%, early retrieval 9%, gastric ulcers ~10%
DJBL/EndoBarrier systematic review/meta-analysis (Chen et al. 2024)
Pooled EWL ~41.3% at 12 months while in situ; pooled early removal ~19%; pooled SAE ~17% including hepatic abscesses
ESG pooled outcomes (IFSO / systematic reviews/meta-analyses)
TBWL ~15-17.6% at 6-12 months; pooled SAE ~1.25% (IFSO review of 15,928 procedures; 194 SAEs)
LAGB long-term revision/removal rates (Froylich et al.; Vinzens et al.; Altieri et al.)
High rates of band removal/revision (e.g., 59.4% band removal in Froylich; overall RC rate ~26.0% for LAGB), weight regain and GERD worsening noted
Teen-LABS (Inge et al. 2018)
In adolescents with T2D, surgical group HbA1c fell from 6.8% to 5.5% vs medical group increased to 7.8% over 2 years; BMI decreased 29% vs increased 3.7%
Leang et al. (2024) robotic vs laparoscopic RYGB meta-analysis
No significant differences in most outcomes; slightly higher 30-day reoperation with robotic (4.4% vs 3.4%) across 82,155 individuals

Policy Revisions

2026-05-01revisionLatest

Replaced references to 'Nonalcoholic Fatty Live Disease (NAFLD)' with 'Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)'.

2026-05-01revisionLatest

Revised planned two-stage procedure coverage criteria: second stage must occur within 2 years, initial BMI threshold retained, and wording changed from 'compliant with nutrition and exercise' to 'adherent to nutrition and exercise'.

2026-05-01

Additional required evaluations

Completion of a preoperative evaluation that includes a detailed weight history, dietary and physical activity patterns
Psychosocial-behavioral evaluation by a professionally recognized behavioral health clinician to screen for risk factors or postoperative challenges
Alternative to psychosocial evaluation
- Participation in a multidisciplinary surgical preparatory regimen (may substitute for individual psychosocial-behavioral evaluation)

Pediatric/adolescent specific criteria

Applies to adolescents aged 12 to 17 years
ONE of the following pediatric thresholds
- Class III obesity (per American Society for Metabolic and Bariatric Surgery definitions)
- Class II obesity in the presence of one or more comorbidities (insulin resistance or type 2 diabetes; poorly controlled hypertension despite pharmacotherapy; hyperlipidemia; obstructive sleep apnea with AHI or RDI ≥ 30; evidence of MASLD; idiopathic intracranial hypertension)
Evaluation at or in consultation with a multidisciplinary center focused on surgical treatment of severe childhood obesity (e.g., accredited adolescent/metabolic bariatric centers or equivalent programmatic components)

Members' records should include at minimum the following

Required documentation for medical necessity review — items below must be present in the member's record:

ALL of the following

History and physical with weight history and BMI calculations (height, weight, dates)
Documentation of comorbid conditions with supporting tests (e.g., labs, imaging, sleep study reports)
Preoperative dietary assessment and records of participation in preparatory programs or multidisciplinary regimen
Psychosocial-behavioral evaluation by a behavioral health clinician with risk assessment and recommendations
Operative reports for prior bariatric procedures when applicable
Endoscopy reports for esophagitis and reflux assessment when relevant
Documentation of attempted non-surgical management prior to revisional procedures (e.g., band adjustments, maximal medical therapy for reflux)
Nutritionist/dietitian notes and documented nutritional plan and follow-up
Polysomnography report when OSA is a listed comorbidity (AHI/RDI values)
For planned staged procedures: documentation of initial BMI ≥ 50 kg/m2 and plan/timing for stage two within 2 years

Revisions affecting planned two-stage procedures

Revisions affecting planned two-stage procedures — summary and operational note:

ALL of the following

Policy revisions clarify criteria for planned two-stage bariatric procedures: initial BMI threshold, timing of second-stage procedure, adherence requirements, and reapplication of medical necessity criteria at second stage
Specific revised criteria text from the brief is not fully present in source; use operational notes below
Operational note: Ensure documentation shows initial BMI ≥ 50 kg/m2, second-stage planned/completed within 24 months, documented nutrition and exercise adherence, and current fulfillment of medical necessity criteria at time of second-stage authorization/review
Revisional bariatric surgery nutritional considerations: a thorough pre- and post-revisional nutritional assessment is required, with documentation of micronutrient status, protein intake adequacy, and a documented plan for long-term nutrition monitoring and supplementation as indicated
For revisional procedures due to mechanical/technical failure or major complication, include evidence of failure (imaging, endoscopy, operative findings) and records of attempted corrective measures where applicable

Overall the evidence base across procedures is judged to be of low-quality (multiple HTAs and evidence reviews). Key limitations include generally short follow-up for many devices and endoscopic approaches, substantial heterogeneity across study designs and populations, and predominance of observational series. Hayes and ECRI/other HTAs conclude that higher-quality randomized controlled trials and standardized reporting with longer follow-up are needed to reduce uncertainty about comparative effectiveness and long‑term safety.

Selected numeric evidence metrics (safety, efficacy, revisions, RCT signals)

DJBL (EndoBarrier) pooled early removal~19% early removal rate

DJBL (EndoBarrier) pooled serious adverse events~17% SAE rate (includes hepatic abscess, device migration, GI hemorrhage, obstruction)

ESG pooled serious adverse events (IFSO/pooled)1.25% pooled SAE rate (194 SAEs among 15,928 procedures)

SADI-S RCT 2‑year superiority resultSADI-S mean %EWL −76.0% vs RYGB −68.1%; MD −6.72% EWL; p=0.026 (superiority at 2 years)

BPD/DS long-term diabetes remission~90% diabetes clinical remission at 10 years (Kapeluto et al.)

LAGB / revision/conversion rate (Altieri et al.)Revisions/conversions rate for LAGB = 26.0% (10-year NY state data)

Overall reoperation rate among bariatric operations (ASMBS task force)6.3% reoperation rate; of reoperations 69.5% corrective vs 30.5% conversions

Notable early removal / intolerance signals with intragastric balloons (REDUCE/DBS)DUO (dual IGB) trial: balloon deflation 6%, early retrieval 9%, gastric ulcers ~10%

Evaluation at or in consultation with a multidisciplinary center focused on surgical treatment of severe childhood obesity (may include accredited adolescent centers by MBSAQIP or programs demonstrating equivalent components)
Multidisciplinary evaluation for pediatric MBS is required
Comprehensive multidisciplinary evaluation including but not limited to bariatric surgeon, pediatric/adolescent medicine specialist or obesity medicine specialist, registered dietitian, behavioral health specialist, and exercise/specialized nursing professionals
Provider action: Multidisciplinary evaluation for pediatric MBS
Documentation of detailed preoperative weight history, dietary and physical activity assessment, and psychosocial-behavioral evaluation by a behavioral health professional to identify risk factors or challenges for postoperative outcomes
ASMBS recommendation

Perioperative and postoperative care elements

Counseling on pregnancy risk and contraception: adolescents must receive counseling on the implications of bariatric surgery for future pregnancy, recommended timing to delay pregnancy after surgery, and contraception options and planning
Provider action: Counseling on pregnancy/contraception after bariatric surgery
Nutritional monitoring and supplementation plan: ongoing nutrition follow-up is required; specific monitoring after revisional procedures such as distalization of Roux-en-Y gastric bypass must include surveillance for protein-calorie malnutrition, micronutrient deficiencies, and tailored supplementation and dietitian follow-up
Provider action: Nutritional monitoring after revisional distalization RYGB
Structured transition plan to adult metabolic and bariatric surgery care, including documented handoff, follow-up schedule, and education on lifelong surveillance needs
ASMBS recommendation

Documentation Required

Documentation callout: Adolescents — provider actions

Adolescent program requirements and transition to adult MBS care: actions required from providers.

Ensure multidisciplinary evaluation is documented: team members, visit notes, and behavioral health assessment.
Document complete prior bariatric surgery details when applicable: operative reports, device details, complications, and prior corrective attempts.
Provide counseling on pregnancy and contraception: document counseling content, recommended delay of conception post-surgery, and contraception plan.
Implement nutritional monitoring particularly after revisional distalization RYGB: document monitoring schedule, labs (protein, iron, B12, folate, vitamin D, calcium, others), supplementation plan, and dietitian follow-up.
Create and document a transition plan to adult MBS care: planned handoff, adult provider identified, and follow-up timeline.

Policy revisions note several procedural list changes: Silastic ring vertical gastric bypass and transoral endoscopic surgery including transoral outlet reduction (TORe) were added to the list of procedures designated unproven/not medically necessary; stomach aspiration therapy was removed from that list; and various transoral endoscopic categories were consolidated (for example, intragastric balloon and gastrointestinal liners now grouped under transoral endoscopic surgery). These added procedures are designated unproven/not medically necessary in the revised policy.

Documentation Required

Document structured diet program completion

Document completion of a structured diet program using acceptable evidence: physician notes; notes from other health care providers; receipts of payment for a structured diet program; or diet/weight-loss logs. For COMAR-regulated fully insured Maryland plans, documentation must show either one structured program of six consecutive months or two structured programs of three consecutive months within the two years immediately preceding the request.

Acceptable evidence: physician notes, HCP notes, receipts for program payment, or diet/weight-loss logs
Timing requirement (COMAR Maryland): one program for 6 consecutive months OR two programs for 3 consecutive months within the prior two years

Documentation Required

Preoperative evaluation and documentation

Provide a comprehensive preoperative evaluation and documentation including an obesity-focused history and physical; detailed weight history (current and prior two-year BMI trend); description of past weight-loss attempts with dates, duration, maintenance, and reasons for discontinuation; and evidence of multidisciplinary preoperative preparation including psychosocial/behavioral evaluation by an appropriately qualified clinician.

Obesity-focused history and physical exam
Weight history with current and two-year BMI trajectory
Attempts at weight loss with dates, duration, outcomes/maintenance, and reasons for discontinuation
Multidisciplinary preparatory regimen participation, including psychosocial/behavioral assessment

Documentation Required

Nutritional screening and monitoring

Perform preoperative nutritional screening for vitamin and mineral deficiencies and document planned postoperative micronutrient monitoring and individualized supplementation. For revisional distalization procedures, document intent for aggressive supplementation and close monitoring when common channel (CC) is < 200 cm or total alimentary limb length (TALL) (AL+CC) is < 400 cm due to elevated risk of macro- and micronutrient deficiencies.

Preoperative screening for vitamin/mineral deficiencies
Planned routine postoperative micronutrient monitoring and individualized supplementation
Aggressive supplementation and regular nutrition monitoring after distalization when CC < 200 cm or TALL < 400 cm

Documentation Required

Behavioral health, pregnancy counseling, pediatric multidisciplinary evaluation, prior-surgery details, and device-specific informed consent/research context

Behavioral health: document involvement of bariatric behavioral health clinicians pre- and post-operatively to identify psychosocial risks and support long-term care. Counseling on pregnancy/contraception: document patient counseling that pregnancy is not recommended during rapid weight loss and contraception planning/ follow-up. Multidisciplinary pediatric MBS evaluation: for patients <18, document referral to a comprehensive multidisciplinary MBS center with holistic assessment of the patient and family, psychosocial/social risks, and program accreditation or MBSAQIP-equivalent components. For subsequent/revision surgery: include date of initial surgery, details of any complications, and a complete staged surgical plan. Device-specific informed consent / research context: for devices/procedures with limited evidence (e.g., DJBL/EndoBarrier, swallowable gastric balloon, and certain SADI-S guidance), document that use is in a research context or under special clinical governance with explicit informed consent per NICE recommendations.

Behavioral health involvement: pre- and postoperative psychosocial evaluation and documented plan for long-term behavioral support
Counseling on pregnancy/contraception: documented counseling and contraception follow-up during rapid weight-loss phase
Multidisciplinary pediatric MBS: referral to accredited comprehensive MBS center and holistic family assessment
Subsequent bariatric surgery: date of initial surgery, complication details (if any), and full staged surgical plan
Device-specific informed consent / research context: document research setting or special governance, consent, and audit for devices with limited evidence (e.g., DJBL/EndoBarrier, swallowable gastric balloon); note NICE recommendations